Analysts See 19% Gains Ahead For FHLC
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 14 2025
0mins
Source: NASDAQ.COM
Fidelity MSCI Health Care Index ETF Analysis: The Fidelity MSCI Health Care Index ETF (FHLC) has an implied analyst target price of $76.32, indicating an 18.99% upside from its current trading price of $64.14.
Notable Holdings with Upside Potential: Key underlying holdings such as uniQure N.V., Viridian Therapeutics Inc., and Cogent Biosciences Inc. show significant potential for growth, with expected price increases of 148.28%, 124.96%, and 69.73% respectively based on analyst targets.
Analyst Views on VRDN
Wall Street analysts forecast VRDN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VRDN is 41.71 USD with a low forecast of 14.20 USD and a high forecast of 61.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Analyst Rating
17 Buy
0 Hold
0 Sell
Strong Buy
Current: 32.170
Low
14.20
Averages
41.71
High
61.00
Current: 32.170
Low
14.20
Averages
41.71
High
61.00
About VRDN
Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of veligrotug in patients with active and chronic TED. It is also conducting two global Phase 3 clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients. Its advanced program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
